Terry Chrisomalis

Summary Dyne Therapeutics, Inc. retains a Strong Buy rating, driven by clinical progress in DM1 and DMD programs targeting significant unmet needs.

Summary Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes.

Summary I am initiating AstraZeneca at a "Strong Buy," driven by robust Q1 2026 revenue growth and portfolio momentum.

Denali Therapeutics (DNLI) maintains a Strong Buy rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum.

I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcoming catalysts.

Summary TG Therapeutics remains a "Strong Buy" as BRIUMVI drives robust revenue growth and pipeline expansions.

Summary Agios Pharmaceuticals, Inc. is initiated at Sell due to pipeline setbacks and intensifying competition in PK activators.

Summary Gilead Sciences is maintained at 'Hold' as the HIV franchise drives growth, but the oncology pipeline requires further progress.

Summary I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma.

Summary Abivax achieved strong phase 3 efficacy for obefazimod in moderate-to-severe ulcerative colitis, but rare cancer cases prompt a downgrade to 'Hold.'